351 related articles for article (PubMed ID: 26086365)
1. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
[TBL] [Abstract][Full Text] [Related]
2. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Gellhaar S; Marcellino D; Abrams MB; Galter D
Genes Brain Behav; 2015 Mar; 14(3):260-70. PubMed ID: 25752644
[TBL] [Abstract][Full Text] [Related]
3. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
4. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
5. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
[TBL] [Abstract][Full Text] [Related]
6. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
7. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
9. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
10. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
11. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Kuo TT; Chen YH; Wang V; Huang EY; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Tseng KY
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902115
[TBL] [Abstract][Full Text] [Related]
12. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
13. Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.
Farrand AQ; Gregory RA; Bäckman CM; Helke KL; Boger HA
Brain Res; 2016 Nov; 1651():88-94. PubMed ID: 27659966
[TBL] [Abstract][Full Text] [Related]
14. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
15. Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Gil SJ; Park CH; Lee JE; Minn YK; Koh HC
Brain Res Bull; 2011 Feb; 84(2):151-6. PubMed ID: 21163338
[TBL] [Abstract][Full Text] [Related]
16. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
18. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
19. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
[TBL] [Abstract][Full Text] [Related]
20. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Carlsson T; Winkler C; Burger C; Muzyczka N; Mandel RJ; Cenci A; Björklund A; Kirik D
Brain; 2005 Mar; 128(Pt 3):559-69. PubMed ID: 15659429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
